Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 9007 results

  1. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  2. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Advanced Pelvic Exenteration surgery for complex pelvic cancers

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [TSID12406]

    Awaiting development Reference number: GID-TA12033 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation [TSID12404]

    Awaiting development Reference number: GID-TA12036 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [TSID12411]

    Awaiting development Reference number: GID-TA12038 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [TSID12412]

    Awaiting development Reference number: GID-TA12039 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [TSID12413]

    Awaiting development Reference number: GID-TA12040 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [TSID12400]

    Awaiting development Reference number: GID-TA12031 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Olezarsen for treating severe hypertriglyceridaemia [TSID12387]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development